Spero therapeutics email format
WebOct 28, 2024 · These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release. Investor Relations Contact: Ted Jenkins Vice... WebJun 27, 2024 · CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug ...
Spero therapeutics email format
Did you know?
WebFounded in 2013 Listed Company "Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. WebContact Spero Therapeutics Investor Contact: [email protected] Media Contact [email protected] Business Development Contact: …
WebJul 21, 2024 · A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.... WebSpero Therapeutics contact info: Phone number: (857) 242-1600 Website: www.sperotherapeutics.com What does Spero Therapeutics do? Spero Therapeutics …
WebMar 30, 2024 · Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and … WebSpero Therapeutics Company Name Spero Therapeutics Main Industry Research & Development, Business Services Website www.sperotherapeutics.com Contact …
WebWebsite http://www.sperotherapeutics.com Industries Biotechnology Research Company size 11-50 employees Headquarters Cambridge, MA Type Public Company Founded 2013 …
WebThe Latest. On April 6, 2024, Spero Therapeutics announced publication in the New England Journal of Medicine (NEJM) the results from the Phase 3 ADAPT-PO clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil hydrobromide (tebipenem HBr). In June 2024, the FDA communicated that it had completed its review of the NDA … dfttoolbox的例子文件qe_pp.pyWebApr 13, 2024 · Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. dfttc5WebMay 3, 2024 · Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including... dft to dctWebEmail Format Management Spero Therapeutics Information We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and … chuyenthamkinyoutubeWebSep 22, 2024 · The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries. Spero Therapeutics receives $66 million upfront, with potential ... chuyen thanh file jpgWebSpero Therapeutics is excited to announce that we are winners of a 2024 CandE Award! Spero ranked #22 out of #132 companies that participated in North America. The CandE Award is a prestigious award in the Talent Acquisition and HR space that recognizes companies who have been identified as providing exceptional candidate care by the … dft toleranceWebOct 15, 2024 · At the end of the first half of this year, Spero Therapeutics had cash and cash equivalents of $99.2 million. Research and development expenses for Q2 of 2024 were $14.4 million compared to $15.6 ... chuyen tactical ct5